On December 14, 2020, ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, announced the closing of its previously announced underwritten public offering of 2,737,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 357,000 additional shares of its common stock, at a price to the public of $76 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately $208 million. All of the shares were offered by ALX Oncology. Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the offering.

Jefferies, Credit Suisse, and Piper Sandler acted as joint book-running managers for the offering. Cantor and UBS Investment Bank also acted as book-running managers for the offering. In addition, LifeSci Capital acted as lead manager for the offering.

The Wilson Sonsini team advising ALX Oncology includes the following attorneys:

Corporate:
Ken Clark
Tony Jeffries
Michael Coke
Christina Poulsen
Kexi Wang
Mary O'Brien

Regulatory:
David Hoffmeister

Please see ALX Oncology’s press release for more information.